# A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Source: https://onco.cc/trials/nct05032040/  
OnCo record `nct05032040` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of vudalimab in ovarian cancer, endometrial cancer, cervical cancer and prostate cancer, run by Xencor, Inc., active and no longer recruiting.

## Summary

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies is a phase 2 interventional study registered as NCT05032040 by Xencor, Inc., with 170 participants enrolled, started 2022-07-21 and due to reach its primary completion in 2025-10-15. Interventions recorded: vudalimab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05032040
- Phase: 2
- Setting: A Phase 2 Study of XmAb20717 in Patients With Selected Gynecological Malignancies and Metastatic Castration-Resistant Prostate Cancer
- Sponsor: Xencor, Inc.
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT05032040: https://clinicaltrials.gov/study/NCT05032040

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [ICON plc](https://onco.cc/companies/icon-plc/), [Xencor](https://onco.cc/companies/xencor/)
- drugs: [Vudalimab](https://onco.cc/drugs/vudalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct05032040.json